Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SOPHiA Genetics Combines In Vivo And In Vitro Cancer Analyses With Enhanced AI Platform

Executive Summary

Clinical genomics company SOPHiA Genetics is integrating new radiomics capabilities to enhance its artificial intelligence (AI) platform SOPHiA, which is already used for analyses of oncology data from liquid biopsy tests. The news marks an increasing trend toward integrating in vivo and in vitro data onto a single diagnostic platform.

Advertisement

Related Content

SOPHiA Buys In More Bioinformatics Know-How For Cancer Genomics
GE And Roche Join Forces In First-Of-Its-Kind Tech Pact
Sophia Genetics' AI Brings In More Standardization To Liquid Biopsies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT122085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel